PremiumClass ActionRocket Pharmaceuticals Faces Legal Storm Over Trial Omission Rocket Pharmaceuticals price target lowered to $11 from $34 at Canaccord Rocket Pharmaceuticals downgraded at Evercore following patient death in study PremiumThe FlyGoldman downgrades Rocket to Sell on ‘surprising and concerning’ update Rocket Pharmaceuticals downgraded to Sell from Neutral at Goldman Sachs Rocket Pharmaceuticals: Buy Rating Affirmed Amid Strategic Adjustments and Financial Resilience PremiumThe FlyRocket Pharmaceuticals downgraded to Hold from Buy at Jefferies Hold Rating Issued for Rocket Pharmaceuticals Amid Uncertainty Following Clinical Hold on RP-A501 Trial Cautious Optimism for Rocket Pharmaceuticals’ RP-A501 Amid Clinical Challenges 
